Summary: | Glycopyrrolate oral solution (Cuvposa) is an anticholinergic drug indicated to reduce chronic severe drooling in patients three to 18 years of age with neurologic conditions (e.g., cerebral palsy [CP]). It is available in a 1 mg/5 mL concentration in 473 mL bottles at a submitted price of $625.00 per bottle, or $6.61 per mL. The recommended starting dose of glycopyrrolate is 0.02 mg/kg three times daily, titrated in increments of 0.02 mg/kg every five to seven days based on therapeutic response and adverse reactions. The maximum recommended dose is 0.1 mg/kg three times daily, not to exceed 1.5 to 3 mg per dose (see Table 11 for further details). For a 30 kg patient, depending on dose, the daily cost of glycopyrrolate at the submitted price may range from $11.98 to $59.46 (see Table 5). The sponsor submitted a cost-utility analysis comparing glycopyrrolate oral solution to no treatment in the indicated population from the perspective of a Canadian publicly funded health care system over a 24-week time horizon
|